Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of Zoom calls, deadlines, and what-not has, of course, returned. The world, after all, keeps spinning, no matter what. So the time has come to grab a cup of stimulation — or a bottle of water, if you prefer — and dig in for another busy day. On that note, here are a few tidbits to get you started. Hope your day is successful, and do keep in touch. …

The world’s biggest drug makers and their trade groups have cut checks to 356 lawmakers ahead of the November election — more than two-thirds of the sitting members of Congress, according to a new STAT analysis. This barrage of contributions accounts for roughly $11 million in campaign giving, distributed via roughly 4,500 checks from the political action committees affiliated with the companies. The examination focused on 23 of the biggest drug makers and the two major trade associations: PhRMA and BIO.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy